Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol
Jennifer Le Guévelou(Inserm), Juliette Thariat(Centre François Baclesse), C. Le Péchoux(Institut Gustave Roussy), Dominique Vaur(Centre François Baclesse), Anne Ducassou(Institut universitaire du cancer de Toulouse Oncopole), Ovidiu Veresezan(Centre Hospitalier Universitaire de Rouen), Christine Lovera(UniCancer Group), Laurence Moureau-Zabotto(Institut Paoli-Calmettes), Colin Debaigt(UniCancer Group), Nicolas Penel(Centre Oscar Lambret), Maria Jolnerovski(UniCancer Group), Céline Bazille(Université de Caen Normandie), David Thibouw(Centre Georges François Leclerc), Alexandre Escande(Centre Oscar Lambret), M. Benchalal(Centre Eugène Marquis), Julien Viotti(Centre Antoine Lacassagne), Esma Saâda-Bouzid(Université Côte d'Azur), Raphaël Serre(Centre Hospitalier Universitaire de Limoges), Marie Pierre Sunyach(Centre Léon Bérard), Nazim Khalladi(Centre François Baclesse)
Cited by 13
Related Papers
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2020|482
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
|Annals of Oncology|2019|282
Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement
|Radiotherapy and Oncology|2020|227